17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well 17-AAG works in treating patients with metastatic
prostate cancer that did not respond to previous hormone therapy. Drugs used in chemotherapy,
such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing.